LungLife AI, INC Health economics publication (0731S)
March 07 2023 - 2:00AM
UK Regulatory
TIDMLLAI
RNS Number : 0731S
LungLife AI, INC
07 March 2023
LungLife AI, Inc.
(the "Company" or "LungLife")
Nodule evaluation using LungLB(R) projected to be cost-effective
in US healthcare system
Data strongly support payor coverage of indeterminate lung
nodule evaluation using LungLB(R) in peer-reviewed publication in
the Journal of Medical Economics.
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces that further to its
announcement on 27 February 2023, the final version of the health
economics publication is now available. There have been no changes
to the results or conclusions, which show LungLB(R) is projected to
be a cost-effective solution for US insurers covering individuals
with indeterminate lung nodules.
The publication can now be accessed here: Journal of Medical
Economics Vol 26
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Virginia Bull / Cameron MacRitchie
/ Lydia Zychowska
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Stephanie Cuthbert / Alice Woodings Mob: 07980 541 893 / 07407 804 654 /
/ Phillip Marriage 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to
lung cancer. Our Vision is to invert the 20:80 ratio such that in
years to come at least 80% of lung cancer is detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBQLLBXXLFBBF
(END) Dow Jones Newswires
March 07, 2023 02:00 ET (07:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024